Evidence map›Paper›PMID 34642878›Full record

ArticleAmerican journal of clinical dermatology2021

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.

Eric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, Kevin L Winthrop, Emma Guttman-Yassky, Karin M Hoffmeister, Alexander Egeberg, Hernan Valdez, Min Zhang, Saleem A Farooqui and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of clinical dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Eric L SimpsonDepartment of Dermatology, Oregon Health and Science University, Portland, OR, USA.
Jonathan I SilverbergDepartment of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Audrey NosbaumDepartment of Allergy and Clinical Immunology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
Kevin L WinthropDepartment of Dermatology, Oregon Health and Science University, Portland, OR, USA.
Emma Guttman-YasskyDepartment of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Karin M HoffmeisterVersiti, Translational Glycomics Center, Blood Research Institute, Milwaukee, WI, USA.
Alexander EgebergDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Hernan ValdezPfizer Inc., New York, NY, USA.
Min ZhangPfizer Inc., La Jolla, CA, USA.
Saleem A FarooquiPfizer R & D UK Ltd., Kent, UK.
William RomeroPfizer Ltd., Surrey, UK.
Andrew J ThorpePfizer Inc., Collegeville, PA, USA.
Ricardo RojoPfizer Inc., Groton, CT, USA.
Susan JohnsonPfizer Inc., Collegeville, PA, USA. Susan.L.Johnson@pfizer.com.ORCID http://orcid.org/0000-0001-5016-5768

Funding

Carbohydrate-Mediated Platelet ClearanceR01HL089224 · NHLBI · VERSITI WISCONSIN, INC. · PI Karin Maria Hoffmeister · 2007 to 2026
$9.3M
NHLBI NIH HHS R01 HL089224
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34642878
PMCPMC9172826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.